We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medtronic has announced the recent introduction of the Medtronic Attain Select
6238 TEL Guide Catheter Set that aids in the safe and effective implantation
of device leads in the veins that serve the left side of the heart for the treatment
of heart failure.
The FDA has approved the GORE TAG Endoprosthesis System, an endovascular grafting
system that is intended to prevent ruptures of descending thoracic aneurysms
by making a new path for blood flow.
Best Manufacturing, an industrial and medical glove maker, and its parent company,
Tillotson, announced the settlement of patent infringement cases pertaining
to its patent for thin disposable nitrile gloves (U.S. Patent No. Re. 35, 616).
Bayer Diagnostics has increased the sensitivity of its automated HBc Total and
HIV 1/O/2 assays for use on the ADVIA Centaur Immunoassay System to improve
laboratories' detection capability for hepatitis B and human immunodeficiency
virus (HIV) infections.
The FDA has approved a clinical trial for a new and much more effective formulation
of MethLock, a catheter lock solution developed by Ash Access Technology, a
Lafayette, Ind., company focused on vascular access medical solutions to prevent
catheter-related bloodstream infections (CRBSI).
EDC Biosystems announced that the U.S. Patent Office has issued U.S. Patent
No. 6,863,362 to the company for claims relating to "Acoustically mediated
liquid transfer method for generating chemical libraries."
Pathway Medical Technologies, a medical device developer that ran out of money
and shut down in November 2004, has been brought back to life with a $10.1 million
investment and a reinvented business model.
Chindex International, an independent American provider of Western healthcare
products distribution and healthcare services in the People's Republic of China,
announced that it has entered into definitive agreements with institutional
accredited investors with respect to the sale of 1,080,397 shares of its common
stock, for an aggregate purchase price of approximately $6.5 million, together
with warrants to purchase an additional 378, 137 shares of its common stock.
Nanogen and Pathway Diagnostics announced that they have entered into a nonexclusive,
worldwide license agreement under which Nanogen will develop diagnostic products
that detect genetic variations associated with responses to antidepressant and
antipsychotic therapeutics.